Mortality Rate of Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Procedure
Posted on: October 13, 2023 *Updated on: May 27, 2024Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for select patients with peritoneal surface malignancies. The procedure involves the surgical removal of visible tumor nodules from the peritoneal cavity, followed by the direct infusion of heated chemotherapy agents into the abdominal cavity to target residual microscopic cancer cells.
The 30-day mortality rate of 1.1% from the University of Nebraska-Omaha Cancer Center for cytoreduction/HIPEC.
The patients’ underlying health status, the progression of the disease, and the presence of other medical conditions can also influence outcomes. While the 1.1% mortality rate for CRS/HIPEC sounds favorable, it’s important to recognize that the overall risk associated with any surgical procedure will depend on a combination of factors, including the surgeon’s experience, the healthcare facility, and the patient’s individual health profile.
For patients considering any surgical intervention, it’s essential to have a comprehensive discussion with their healthcare team to understand the potential risks and benefits in the context of their individual health status and the specifics of their disease.